STANDARD BIOTOOLS INC. (LAB) earnings date, results and what the price requires

    Nasdaq · SEC CIK 0001162194 · SEC filings checked Oct 17, 2026

    Next report
    Nov 5, 2026
    Estimated from reporting history (92-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
    Last close
    $0.63
    Polygon.io daily close, Oct 16, 2026. End of day, not live.
    Trailing diluted EPS
    $0.22
    Sum of quarters ending Jun 30, 2026, Mar 31, 2026, Dec 31, 2025, Sep 30, 2025 · P/E 2.9

    Previous results (SEC filings)

    Quarter endedReportedRevenueNet incomeDiluted EPSSource
    Jun 30, 2026Aug 5, 2026$20.1M$-26.8M$-0.07Filing
    Mar 31, 2026May 5, 2026$21.1M$127.1M$0.33Filing
    Dec 31, 2025Jan 30, 2026$23.8M$19.3M$0.05Filing
    Sep 30, 2025Nov 4, 2025$19.6M$-34.7M$-0.09Filing
    Jun 30, 2025Aug 11, 2025$21.8M$-33.5M$-0.09Filing
    Mar 31, 2025May 6, 2025$20.2M$-26.0M$-0.07Filing
    Dec 31, 2024Jan 13, 2025$890,000$-34.1M$-0.06Filing
    Sep 30, 2024Oct 30, 2024$22.1M$-26.9M$-0.07Filing

    What would STANDARD BIOTOOLS INC. have to report for its valuation to change?

    At $0.63, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -24.6% a year, to $0.05. On that path the next quarter needs diluted EPS near $-0.07, against $-0.09 in the quarter ended Sep 30, 2025.

    Are you considering buying, or do you already own shares?

    Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.

    ResultOriginalYours
    Required EPS growth / year-24.6%-24.6%
    EPS needed in final year$0.05$0.05

    Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.

    Prepare for earnings across my investments — $399/month

    Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. LAB goes in with your buy-or-wait comparison and assumptions preserved.

    Start Desk — $399/month

    Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.